Abstract
Zerumbonoquinone 10 and zerumbonaminone 11 have been designed to release toxic moieties selectively and preferentially under reductive conditions. These compounds were synthesized by coupling the quinone delivery system with zerumbone alcohol 8 and amine 9. All compounds were evaluated for cytotoxicity against KB (non reductase overexpressing cells), NCI-H187 and MCF-7 (reductase overexpressing cells) and normal cells (Vero cells). Bioreductive compounds 10 and 11 were found to act as bioreductive anticancer agents exhibiting less cytotoxicity than the parents 8 and 9 in KB cells with good stability, and were partially bioreductively active against MCF-7 and NCI-H187 cells.
Keywords: Bioreductive, KB, NCI-H187, MCF-7, Zerumbone derivatives, Zingiber zerumbet Smith, Anticancer, sesquiterpene, antiproliferative, antileukemia, stereochemistry, tumor cells, tumor targeting drug delivery system (TDDS), intramolecular cyclization, non-toxic lactone species III
Letters in Drug Design & Discovery
Title: Anticancer Activity of the Bioreductive and Non-Bioreductive Zerumbone Derivatives
Volume: 8 Issue: 6
Author(s): Siripit Pitchuanchom, Uraiwan Songsiang, Natthida Weerapreeyakul and Chavi Yenjai
Affiliation:
Keywords: Bioreductive, KB, NCI-H187, MCF-7, Zerumbone derivatives, Zingiber zerumbet Smith, Anticancer, sesquiterpene, antiproliferative, antileukemia, stereochemistry, tumor cells, tumor targeting drug delivery system (TDDS), intramolecular cyclization, non-toxic lactone species III
Abstract: Zerumbonoquinone 10 and zerumbonaminone 11 have been designed to release toxic moieties selectively and preferentially under reductive conditions. These compounds were synthesized by coupling the quinone delivery system with zerumbone alcohol 8 and amine 9. All compounds were evaluated for cytotoxicity against KB (non reductase overexpressing cells), NCI-H187 and MCF-7 (reductase overexpressing cells) and normal cells (Vero cells). Bioreductive compounds 10 and 11 were found to act as bioreductive anticancer agents exhibiting less cytotoxicity than the parents 8 and 9 in KB cells with good stability, and were partially bioreductively active against MCF-7 and NCI-H187 cells.
Export Options
About this article
Cite this article as:
Pitchuanchom Siripit, Songsiang Uraiwan, Weerapreeyakul Natthida and Yenjai Chavi, Anticancer Activity of the Bioreductive and Non-Bioreductive Zerumbone Derivatives, Letters in Drug Design & Discovery 2011; 8 (6) . https://dx.doi.org/10.2174/157018011795906811
DOI https://dx.doi.org/10.2174/157018011795906811 |
Print ISSN 1570-1808 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-628X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Ocular Toxicities in Cancer Therapy: Still Overlooked
Current Cancer Therapy Reviews Chitosan Anchored Nanoparticles in Current Drug Development Utilizing Computer-Aided Pharmacokinetic Modeling: Case Studies for Target Specific Cancer Treatment and Future Prospective
Current Pharmaceutical Design The Use of Nitric Oxide Synthase Inhibitors in Inflammatory Diseases: A Novel Class of Anti-Inflammatory Agents
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Palladium (II) Complex Enhances ROS-Dependent Apoptotic Effects <i>via</i> Autophagy Inhibition and Disruption of Multiple Signaling Pathways in Colorectal Cancer Cells
Anti-Cancer Agents in Medicinal Chemistry Hyaluronic Acid: Targeting Immune Modulatory Components of the Extracellular Matrix in Atherosclerosis
Current Medicinal Chemistry A Systemic Approach to Cancer Treatment: Tumor Cell Reprogramming Focused on Endocrine-Related Cancers
Current Medicinal Chemistry Cystic Fibrosis, Vector-Mediated Gene Therapy, and Relevance of Toll-Like Receptors: A Review of Problems, Progress, and Possibilities
Current Gene Therapy Pharmacological Inhibition of the Bcl-2 Family of Apoptosis Regulators as Cancer Therapy
Current Molecular Pharmacology The Anticancer Properties of Dietary Polyphenols and its Relation with Apoptosis
Current Pharmaceutical Design Long Non-Coding RNA: An Emerging Paradigm of Pancreatic Cancer
Current Molecular Medicine The Role of Placental Carbonyl Reducing Enzymes in Biotransformation of Bupropion and 4-methylnitrosamino-1-(3-pyridyl)-1-butanone
Drug Metabolism Letters Recent Developments in Chimeric NSAIDs as Anticancer Agents: Teaching an Old Dog a New Trick
Mini-Reviews in Medicinal Chemistry Novel Curcumin Inspired Antineoplastic 1-Sulfonyl-4-Piperidones: Design, Synthesis and Molecular Modeling Studies
Anti-Cancer Agents in Medicinal Chemistry Oncogene Expression Modulation in Cancer Cell Lines by DNA G-Quadruplex-Interactive Small Molecules
Current Medicinal Chemistry Ginsenoside Rh2 Improves the Cisplatin Anti-tumor Effect in Lung Adenocarcinoma A549 Cells via Superoxide and PD-L1
Anti-Cancer Agents in Medicinal Chemistry An Overview on Keratinocyte Growth Factor: From the Molecular Properties to Clinical Applications
Protein & Peptide Letters Selumetinib in Advanced Non Small Cell Lung Cancer (NSCLC) Harbouring KRAS Mutation: Endless Clinical Challenge to KRAS-mutant NSCLC.
Reviews on Recent Clinical Trials SUMOylation Regulation of Retina Development and Functions
Current Molecular Medicine Therapeutic Potential of Drug Delivery by Means of Lipid Nanoparticles: Reality or İllusion?
Current Pharmaceutical Design Novel Antitumor Strategies Using Cytokine PEDF for Prostate Cancer Therapy
Current Angiogenesis (Discontinued)